Targeting diabetic kidney disease
Oct. 12, 2018—Pathways activated by the epidermal growth factor receptor may be attractive targets to treat diabetic kidney disease, according to new findings from Vanderbilt investigators.
Glowing receptors help find and track cancerous growth
May. 18, 2017—Under the microscope, they sparkle like emeralds, these molecules that may hold a key to understanding — and stopping — cancerous growth.
New target for colorectal cancer
Mar. 17, 2017—Vanderbilt investigators have discovered that activated epidermal growth factor receptor may be a target for therapies to prevent colorectal cancer development.
New fund honors spirit of Cohen’s innovative research
Aug. 25, 2016—When Tom Daniel, M.D., joined the Vanderbilt University faculty in December 1986, Stanley Cohen, Ph.D., had just been awarded the Nobel Prize in Physiology or Medicine for his discovery of epidermal growth factor (EGF).
Probing mutant EGF receptor regulation
Oct. 10, 2013—Understanding the regulation of mutant EGF receptors commonly found in lung cancers could lead to new targeted therapies.
VU study identifies new mechanism for cancer development
Jun. 6, 2013—Researchers at Vanderbilt University Medical Center led by a 32-year-old postdoctoral fellow have discovered a new mechanism for the development of cancer that is challenging conventional scientific wisdom.
Plant compound stops colon cancer cells
Mar. 29, 2013—Berberine, an herbal remedy for diarrhea and intestinal parasites, may be useful in colon cancer therapy.